WO2008121442A3 - Pa28-gamma regulation in cells - Google Patents

Pa28-gamma regulation in cells Download PDF

Info

Publication number
WO2008121442A3
WO2008121442A3 PCT/US2008/053444 US2008053444W WO2008121442A3 WO 2008121442 A3 WO2008121442 A3 WO 2008121442A3 US 2008053444 W US2008053444 W US 2008053444W WO 2008121442 A3 WO2008121442 A3 WO 2008121442A3
Authority
WO
WIPO (PCT)
Prior art keywords
gamma
regulating
methods
cells
compositions
Prior art date
Application number
PCT/US2008/053444
Other languages
French (fr)
Other versions
WO2008121442A2 (en
Inventor
Ruiwen Zhang
Zhuo Zhang
Original Assignee
Uab Research Foundation
Ruiwen Zhang
Zhuo Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uab Research Foundation, Ruiwen Zhang, Zhuo Zhang filed Critical Uab Research Foundation
Publication of WO2008121442A2 publication Critical patent/WO2008121442A2/en
Publication of WO2008121442A3 publication Critical patent/WO2008121442A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods and compositions for regulating PA28-gamma are described that are useful in treating cancer. The methods for regulating PA28-gamma involve preventing PA28-gamma from mediating an interaction between MDM2 and p53, for example, by promoting cell death in a cancer cell or by treating cancer in a subject by regulating PA28-gamma. The compositions for regulating PA28-gamma include, for example, antibodies to PA28-gamma, double stranded RNA, and antisense oligonucleotides. Additionally, methods for decreasing expression of PA28-gamma, methods for detecting an agent that blocks PA28-gamma function, and isolated cells that do not express PA28-gamma are also described.
PCT/US2008/053444 2007-02-09 2008-02-08 Pa28-gamma regulation in cells WO2008121442A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88895307P 2007-02-09 2007-02-09
US60/888,953 2007-02-09

Publications (2)

Publication Number Publication Date
WO2008121442A2 WO2008121442A2 (en) 2008-10-09
WO2008121442A3 true WO2008121442A3 (en) 2009-04-09

Family

ID=39808842

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/053444 WO2008121442A2 (en) 2007-02-09 2008-02-08 Pa28-gamma regulation in cells

Country Status (1)

Country Link
WO (1) WO2008121442A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5409636B2 (en) 2008-08-29 2014-02-05 国立大学法人大阪大学 Anti-hepatitis C virus composition
WO2016065044A1 (en) * 2014-10-21 2016-04-28 Memorial Sloan-Kettering Cancer Center Methods for drug discovery

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050267037A1 (en) * 2002-11-06 2005-12-01 Dana-Farber Cancer Institute, Inc. Methods and compositions for treating cancer using proteasome inhibitors
WO2006032631A1 (en) * 2004-09-22 2006-03-30 Janssen Pharmaceutica N.V. Inhibitors of the interaction between mdm2 and p53

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050267037A1 (en) * 2002-11-06 2005-12-01 Dana-Farber Cancer Institute, Inc. Methods and compositions for treating cancer using proteasome inhibitors
WO2006032631A1 (en) * 2004-09-22 2006-03-30 Janssen Pharmaceutica N.V. Inhibitors of the interaction between mdm2 and p53

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MU-SHUI DAI ET AL.: "Regulation of the MDM2-p53 Pathway by Ribosomal Protein L11 Involves a Post-ubiquitination Mechanism", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 281, no. 34, 25 August 2006 (2006-08-25), pages 24304 - 24313 *
T. OKAMURA ET AL.: "Abnormally High Expression of Proteasome Activator gamma in Thyroid Neoplasm", THE JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 88, no. 3, 2003, pages 1374 - 1383 *
UTE M. MOLL ET AL.: "The MDM2-p53 Interaction", MOLECULAR CANCER RESEARCH, vol. 1, December 2003 (2003-12-01), pages 1001 - 1008 *

Also Published As

Publication number Publication date
WO2008121442A2 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
WO2010018563A3 (en) Compositions and methods for the prognosis of lymphoma
WO2006076691A8 (en) Irta-2 antibodies and their uses
WO2008109465A3 (en) Nucleic acid compounds for inhibiting fgfr gene expression and uses thereof
WO2005097185A3 (en) Irta-5 antibodies and their uses
WO2006138275A3 (en) Compositions and methods for treating and diagnosing cancer
WO2006073601A3 (en) Methods and compositions for rna interference
WO2011156654A3 (en) Pathways characterization of cells
SG170006A1 (en) Monoclonal antibodies against cd30 lacking fucosyl residues
WO2007014075A3 (en) Rnai modulation of the rho-a gene in research models
WO2009134027A3 (en) Anti-nucleic acid antibody inducing cell death of cancer cells and composition for preventing or treating cancers comprising the same
WO2005089735A3 (en) Compositions and methods for treating lung cancer
WO2009131887A3 (en) Methods of using mir210 as a biomarker for hypoxia and as a therapeutic agent for treating cancer
WO2009102569A3 (en) Cell lines and methods for making and using them
WO2009149359A8 (en) Survival predictor for diffuse large b cell lymphoma
WO2010120541A3 (en) Compositions and methods for modulating the activity of complement regulatory proteins on target cells
WO2005090572A3 (en) Compositions and methods for treating pancreatic cancer
WO2009029293A3 (en) Nucleic acid compounds for inhibiting myc gene expression and uses thereof
MX2010005324A (en) Compositions and methods for inhibiting tumor progression.
WO2006116192A3 (en) Irta-1 antibodies and their uses
WO2010017311A3 (en) Nucleic acid compounds for inhibiting birc5 gene expression and uses thereof
WO2008121442A3 (en) Pa28-gamma regulation in cells
WO2009104896A3 (en) Nucleic-acid pharmaceutical composition for cancer therapy
WO2010096754A8 (en) Compositions and methods to prevent and/or treat cancer with pa -card
WO2004076623A3 (en) Rna-interference for znfn3a1-gene as a method for inhibiting cancer cell growth
WO2008109469A3 (en) Nucleic acid compounds for inhibiting pcna gene expression and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08780406

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08780406

Country of ref document: EP

Kind code of ref document: A2